



The medtech company THERACLION obtains €8.5 million in R&D funding from OSEO Innovation

Paris, January 10th 2009 - [Theraclion](#), the only medtech company in the world developing an innovative technology for the treatment of hyperparathyroidism¹, today announced that it has been granted €8.5 million in R&D funding by OSEO (the French state innovation agency) as part of the TUCE strategic industrial innovation project on elastography-guided ultrasound therapy. The ultrasound company [SuperSonic Imagine](#) will also participate in the Theraclion-driven project.

The €8.5 million in funding comes as a direct, €3.5 million grant and €5 million in reimbursable advances. In all, €6.9 million of the total amount will be attributed to Theraclion, with €1.6 going to SuperSonic Imagine. After €500,000 in 2005 and €1.3 million in 2007, this is the third time that OSEO has provided Theraclion with financial support.

"We are particularly proud to see that OSEO has given our company a vote of confidence by awarding significant funding for the third time running. We shall pursue our clinical trials (the interim results of which are very convincing) and prepare the forthcoming commercialization of our products. We are the only company in the world to use ultrasound and our "UNIS" method in the treatment of hyperparathyroidism and our strategy is also to explore new clinical applications to broaden our field of opportunities," says Ismaël Nujurally, CEO, Theraclion.

"As part of this ambitious programme, the added value contributed by SuperSonic Imagine and its Aixplorer product relates to how Theraclion's therapeutic system is guided. Very high-resolution ultrasound imaging and the superposition of ShearWave elastographic information (a measure of tissue hardness) enable us to determine the site, extent and degree of necrosis created by the Theraclion device," added Jacques Souquet, PhD, CEO at SuperSonic Imagine.

At present, hyperparathyroid patients have to choose between an expensive chronic drug treatment or surgery, with its inherent risks. By leveraging its proprietary "Ultrasound Non-Invasive Surgery" ("UNIS" method), Theraclion is developing medical technology which offers a simple, non-invasive, lower-cost, outpatient-based alternative for treating this condition. Thanks to the "UNIS" method, the high-intensity, focused ultrasound (HIFU) treatment is performed under analgesia and takes around 30 minutes. The target is identified using diagnostic ultrasound and then (thanks to

¹ Today, Hyperthyroidism (increased secretion of parathyroid hormone by the parathyroid glands causing phosphocalcic dysfunction leading to bone decalcification) affects hundreds of thousand people worldwide.

the millimeter accuracy of HIFU beams) only target tissue is destroyed. After the treatment, a blood test is used to check the patient's parathyroid hormone, calcium and phosphate levels.

About Theraclion

The Paris-based medtech specialist Theraclion was spun out from Edap-Technomed in 2004. By leveraging its proprietary "Ultrasound Non-Invasive Surgery" ("UNIS" method), Theraclion develops, produces and commercializes devices for non-invasive, outpatient treatment of primary and secondary hyperparathyroidism. The technology uses diagnostic ultrasound to identify the target and then high-intensity ultrasound to coagulate the tissue - thus enabling patients to avoid burdensome drug treatment and the risks of surgery. Primary hyperparathyroidism has a potential market of over €300 million and secondary hyperparathyroidism corresponds to a potential of 1.5 million easily accessible patients on dialysis. As of today, Theraclion raised €5.1 million from Truffle Capital, one of its founding investor. Theraclion is primarily responding to the needs of clinics and hospitals in Europe, the United States and Asia. The company has initiated procedures for gaining market approval from the United States Food and Drug Administration (FDA). The United States alone represents half of the global market. For more information on Theraclion, visit <http://www.theraclion.fr/>

About SuperSonic Imagine

SuperSonic Imagine, based in Aix-en-Provence, France, is a young, innovative, multicultural company with a commitment to providing advanced technology to improve medical diagnosis. Founded in 2005 by world-renowned ultrasound and medical imaging research scientists, SuperSonic Imagine has developed Aixplorer™, an ultrasound system with a revolutionary imaging technology. With close to 100 employees in offices on 4 continents, the company holds twenty-one international patents and submissions that are solely owned and solely used by SuperSonic Imagine. For more information on SuperSonic Imagine, visit <http://www.supersonicimagine.fr/>

###

This press release may contain forward-looking statements. As such, they do not guarantee future performance; there are risks and uncertainties. Future scientific, preclinical, clinical, regulatory, manufacturing, financial, commercial and business outcomes may be substantially different from those suggested by the forward-looking statements. The forward-looking statements are effective only as per the date at the top of this press release.

Press and Analyst Contacts

Alize RP

Caroline Carmagnol

Tel.: +33 664 189959

caroline@alizerp.com

Charles Catherinot

Tel.: +33 141 220730

charles@alizerp.com

Theraclion

Ismaël Nujurally

Tel.: +33 153 103090

ismael@theraclion.fr